

Lung Carcinoma: Diagnosis & Treatment

Monika Mangla and Bala Dhiman

Department of Chemistry, UIS, Chandigarh University

ABSTRACT

Cancer in the lungs is the main issue that leads to death around the globe. Non-small cell lung cancer (N-SCLC) and small cell lung cancer (SCLC) are two different lung cancers known so far. In spite of all advances in the diagnosis and their standard treatments, non-small cell lung cancer is only analyzed at the advanced stages and has a poor prognosis. Its treatment and avoidance are important requirement which can only be possible by the better understanding of the how it happen i.e. the root of cancer cell and development of cancer cells and then one will able to treat it properly and remove it from the root.

INTRODUCTION

Lung carcinoma is due the uncontrolled growth of cells in tissue of the lungs. By the process of metastasis, it may also spread nearby part of the lungs. Stubborn cough, hoarseness, change in breathing, wheezing, headache, chest pain, weight loss, bone pain, are some of the early stage symptoms that a person can notice. Smoking for long-term and also air pollution are the major risk factors that lead to growth in cancer cells. Treatment for this could be surgery, chemotherapy, and radiotherapy.

Non-small cell lung cancer can be characterized as adenocarcinoma, squamous-cell carcinoma, and substantial cell lung cancer. Smoking a cigarette causes a broad range of lung cancer, however, is mostly connected with squamous-cell carcinoma and small cell lung cancer. A patient who has never smoked, have adenocarcinoma type of cancer. Lung cancer risk factor can also be due to inherited cancer syndromes may caused by abnormal germ-line mutations in retinoblastoma and gene-line mutation in the epidermal growth receptor gene¹⁻². Lung disease abnormality and increase in risk factor with few DNA rebuild capacity that results in gene-line alteration in nucleotide gene. Enhanced expression of repaired genes and DNA synthesis, including RRM-1 and ERCC-1, in NSCLC gives better


prognosis generally, however, there are no advantage of using Pt-based chemotherapy presents unusual gene required for the development of various histological types of lung cancer. Society aim's to improve public awareness of cancer health, its precaution, detection and then treatment of this disease and also the advancement in technology for patients to enhance their care. National and International Society of Senology aims to improve the quality of cancer health assistance across the globe. The main aim of these societies is to distribute the scientific knowledge to oncologists so that they can work together and can provide better service to the patients and reduce the risk factor for cancer problems^{3,4}. Access to internet plays an important role in providing the information and current research idea across the world.

CAUSES


In 2015, diagnoses of lung disease within 1.8 million people and recorded up to 1.6 million deaths⁵⁻¹³. American Cancer society in United States of America has estimated the lung cancer rate in 2018 across the world. About 121,680 men and approx 112,350 women were infected with lung cancer and 154,050 death cases were recorded. This makes the lung cancer, the most widely recognized reason for death in males and after breast cancer, second most common disease in females. On diagnosis, it was found that the age of 70 is the most widely recognized age for lung cancer. 17.4% of individuals in UK diagnosed to have lung cancer survival of five years after the diagnosis, while results are worse in the developing country.

Smoking cigarettes and tobacco are the main cause of lung cancer. Cigarette's smoke contains approx. 73 known cancer-causing agents, including benzo[a]pyrene, NNK, 1,3-butadiene and a radioactive isotope of Po and Po-210. Benzo[a]pyrene is an aromatic compound that can be found in tobacco smoke, coal tar and many foods especially in grilled meats. BPDE (diol epoxide metabolites) react and bind to DNA, which results in mutations and eventually cause cancerit effects on number white blood cells the bodies first line of diffence to fight infections this results in decrease of immuno-receptors which turn the white blood cells in macrophage it also reduces the function of testicles and production of sperms. NNK also known as 4-methylnitrosamino)—(3-pyridin)-1-butanone is a main component of tobacco-specific nitrosamine which play a key in


carcinogenesis. The amount of NNK delivered in cigarette smoke is ranged from 30-280 ng/cigarette in one study and 12-110 ng/cigarette.



benzo[a]pyrene




buta-1,3-diene




N-methyl-*N*-(4-oxo-4-(pyridin-3-yl)butyl)nitrous amide

The non-smokers also infected by lung cancer due to passive smoking which means the inhaling of smoke from another's¹⁴⁻²⁰. in 5th World Congress, Professor G.G. Chen from University of Chinese of Hong Kong in China presented on the stem Cell and Cell Research about Thromboxane (A2 and B2) in smoking induced by lung carcinogenesis. From Baskent UFM in Turkey a doctor named Sule Akcay depict that smoking is the high risk factor for the occurrence of lung cancer²¹⁻²⁴. Apart from these articles, workshops, conferences, symposiums, also gave a great exposure to health information and advance technologies that are invented in the today's generation. 16th Global Annual Oncologist Meeting that held in 2017 in Dubai, Oncologists Meeting at Cologne and Germany will deal with Prevention, Diagnosis, and Treatment of the Lung Cancer and its new innovative techniques²⁵⁻²⁹.



Thromboxane B2



Thromboxane A2

DEVELOPMENT IN TECHNOLOGIES IN LUNG CANCER

It is now clear that Lung Cancer is more common, so several researchers who are expert particularly in recognizing, conducting and guiding the precautions of Lung cancer and these specialists are well known as Pulmonologist³⁰⁻³⁵. Molecular figuration, including the figuration of proteins and qualities, the guiding of treatment can enhance the efficient results with non-small cell lung cancer (NSCLC). The micro-array techniques profile the result of a varied number of genes at the same time and can measure the quantity of this lung cancer content across the world. Gene expression profile associated with the sub-type of N-SCLC and with reduced reoccurrence-free or general existence has been identified. Profiling of mRNA expressions and genome gives a lack of quality or quantity of picture required for the heterogeneity of non-small cell lung cancer. Protein levels do not generally associate with the levels of mRNA and do not reveal the information on post-translational changes or protein-protein interactions. In this way, protein based figuring is most likely going to be necessitous in the complex protein-signal system and advancement in molecular signatures that determine the reaction treatment³⁶⁻⁴⁰.

CONCLUSION

Lung sickness is most noticeable and prevalent across the globe. The development of numerous advanced technologies to decrease the death rate due to Lung cancer. Receptor of Epidermal growth gene modifications has been done in various lung cancers; thus, the recognition of EGFR mutations could be prompt to early cancer detection of these mutations. In spite of direct DNA sequencing detection method, this new technique depends on recombinase polymerase amplification (RPA), allele-specific amplification (ASA), SYBR Green I (SYBR), peptide nucleic acid (PNA) referred to as the AS-RPA-PNA-SYBR (ARPS) system. All these informations can be recall in open access health care survey which shows these novel techniques and innovative research ideas taking place in the field of lung diseases. Many experts share their ideas; suggestions through the open access survey which can be delivered to all in order gain knowledge and information on lung diseases. Although, lung diseases are the major cause for death, the developed techniques and awareness among people through the literature survey have given new hope to the patients to overcome the rate of mortality

REFERENCES-

1. Mathioudakis A, Hardavella G. From Lung Cancer Screening to Targeted Therapies: The Endless Race against Lung Cancer Morbidity and Mortality. *J Lung Cancer Diagn Treat.* (2016);1:e101.
2. Das S, et al. A Prospective Study to Evaluate Clinical Radiation Induced Pneumonitis in Lung Cancer Patients and its Dose Response Relationship with Radiotherapy. *J Lung Cancer Diagn Treat.* (2016);1:101.
3. Foroughi F and Hosseini H .Small Intestinal Obstruction due to Metastasis from Marjolin's Ulcer: Report of a Case and Review of the Literature. *J Clin Exp Oncol.* (2014);3:3.
4. Çetin B, et al. Peroxidation Products and Antioxidant Enzyme Activities in Multinodular Goiter and Papillary Thyroid Cancer Patients. *J Clin Exp Oncol.* (2014);3:3.
5. Sandra SH, et al. Pleomorphic Lobular Carcinoma of the Breast: A Review of 35 Cases at a Single Institution. *Breast Can Curr Res.* (2016);1:105.
6. Meredith I, et al. Mammographic Surveillance after Breast Reconstruction-Is Imaging Necessary?. *Breast Can Curr Res.* (2016);1:106
7. Rahmani S, et al. The Clinical and Histopathological Significance of Performing Surgical Cavity Random Biopsy in Breast Conserving Surgery on Disease Course and Local Recurrence. *Breast Can Curr Res.* (2016); 1:104
8. Smichkoska S and Lazarova E. Long Term Trastuzumab in Metastatic Setting of the Patients with HER2 Positive Breast Cancer. *J Blood Lymph.* (2016);1:103.
9. Khawaja S, et al. A Comparison Between Oncoplastic Breast Conserving Surgery and Standard Wide Local Excision: A UK Experience. *J Blood Lymph.* (2015);1:102.
10. Andres Gomez .The Mammi Breast Pet. A New Weapon for the Diagnosis of Breast Cancer. *J Blood Lymph.* (2015);1:e102
11. Carmichael AR, et al. What is the Impact of Lifestyle on the Incidence of Cancer? *J Blood Lymph.* (2015); 1:e101
12. Singh A and Arora D. A Case of Breast Cancer Recurrence at the“Match Line”. *J Blood Lymph.* (2015);1:101.
13. Andres Gomez .The Mammi Breast Pet. A New Weapon for the Diagnosis of Breast Cancer. *J Blood Lymph.* (2015);1:e102
14. Ahmad A, et al. Kras, Braf, PIK3CA and EGFR Gene Mutations are Associated with Lymph Node Metastasis and Right Sided Colon Carcinoma. *J Cancer Sci Ther .* (2016);8:122-129.
15. Álvarez-Bañuelos MT, et al. Prognostic Factors Associated with Survival in Women with Breast Cancer from Veracruz, Mexico. *J Cancer Sci Ther.* (2016);8:092-098.
16. Gayatri Devi V, et al. Therapeutic Potentials of CD151 shRNA in Targeting Metastasis of Triple Negative Breast Cancer Cell Line MDA-MB-231. *J Cancer Sci Ther .* (2016);8:104-112.

17. Tot T and Gere M. Radiologically Unifocal Invasive Breast Carcinomas: Large-Section Histopathology Correlate and Impact on Surgical Management. *J Cancer Sci Ther.* (2016);8:050-054.
18. García-Novoa A and Acea-Nebril B. Controversies in Axillary Treatment of Breast Cancer Patients and Metastatic Sentinel Lymph Node. *J Cancer Sci Ther.* (2016);8:066-068.
19. Peterson HE, et al. Stereotactic Radiosurgery is a Safe and Effective Method of Prolonging Survival and Managing Symptoms in Patients with Brainstem Metastases *J Cancer Sci Ther.* (2015);7:192-197.
20. Heidari A. Linear and Non-Linear Quantitative Structure-Anti-Cancer-Activity Relationship (QSACAR) Study of Hydrous Ruthenium (IV) Oxide (RuO₂) Nanoparticles as Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Anti-Cancer Nano Drugs. *J Integr Oncol.* (2016);5:e110.
21. Eugeniu B, et al. Dynamic Changes of Molecular Markers during Natural History in Metastatic Melanoma: Ethical Issues and Lessons to Learn. *J Integr Oncol.* (2016);5:176.
22. Maciej P, et al. Mandibular Reconstruction with Osteo-cutaneous Free Flaps in a Patient after Extensive Surgery Supported with 3D Printed Models. *J Integr Oncol.* (2016);5:177.
23. Filho RSO, et al. Main Barriers in Control of Energy-Protein Deficit in Critical Oncologic Patient at Nutritional Risk. *J Integr Oncol.* (2016);5:156.
24. Mastrangelo D, et al. The Cure from Nature: The Extraordinary Anticancer Properties of Ascorbate (Vitamin C). *J Integr Oncol.* (2016);5:157.
25. Lai-Tiong F. Chemotherapy-Induced Nausea and Vomiting: An Oncology-Day Unit Experience. *J Integr Oncol.* (2016);5:158.
26. Mukherjee G, et al. Analysis of Clinico-Pathological Characteristics of Indian Breast Cancers Shows Conservation of Specific Features in the Hormone Receptor Sub-Types. *J Integr Oncol.* (2016);5:159.
27. Giulio GM, et al. Local Resections and Prosthetic Reconstructions in Solitary Bone Metastases of the Limbs According to Histotypes. *J Integr Oncol.* (2016);5:161.
28. Couderc AL, et al. Prognostic Factors in Elderly Patients with Multiple Myeloma Treated with Weekly Bortezomib. *J Integr Oncol.* (2016);5:162.
29. Cheng Q, et al. Meta-analysis of CXCR7 Expression Related to Clinical Prognosis in Cancers. *J Integr Oncol.* (2016);5:163.
30. Pinho L, et al. Molecular Targets in Lung Cancer Therapy: A Current Review. *J Integr Oncol.* (2015);4:148.
31. Chang H, et al. Neoadjuvant Chemotherapy of Three Cycles or More Improve Survival of Patients with N2-3 Nasopharyngeal Carcinoma. *J Integr Oncol.* (2015);4:149.
32. Alvarez AM, et al. Primary cns Lymphoma: Analysis of Treatment by Gamma- Knife Radiosurgery and Chemotherapy in a Prospective, Observational Study. *J Integr Oncol.* (2015);4:150.

33. AlOtaibi SM, et al. Functional Assessment of Quality of Life Using EORTC QLQ-CR29 in Patients with Colon Cancer at King Abdulaziz University Hospital. *J Integr Oncol.* (2015);4:151.
34. Gupta AA, et al. Unconventional Causes of Conventional Oral Cancer. *J Integr Oncol.* (2015);4:152.
35. Choe EK and Kang HY. The Serum Carcinoembryonic Antigen is Associated with HbA1c in Korean NonSmokers. *J Integr Oncol.* (2015); 4:153.
36. Huang C, et al. The Association between mrna Expression Levels of Ephx1 and Prognosis of Acute Myeloid Leukemia. *J Integr Oncol.* (2015);4:154.
37. Kawata N, et al. Kidney Clamp by Using Intestinal Forceps during Nephron Sparing Surgery. *J Integr Oncol.* (2015);4:155.
38. Tabouret E, et al. Bevacizumab Trough Concentration in Recurrent Glioblastoma Patients. *J Integr Oncol.* (2015);4:138.
39. Farsalinos, Konstantinos; Gillman, Gene; Poulas, Konstantinos; Voudris, Vassilis (2015). "Tobacco-Specific Nitrosamines in Electronic Cigarettes: Comparison between Liquid and Aerosol Levels". *International Journal of Environmental Research and Public Health*. 12 (8): 9046–53. doi:10.3390/ijerph120809046. PMC 4555263. PMID 26264016.
40. Djordjevic, M. V.; Stellman, S. D.; Zang, E (2000). "Doses of Nicotine and Lung Carcinogens Delivered to Cigarette Smokers". *Journal of the National Cancer Institute*. 92 (2): 106–11. doi:10.1093/jnci/92.2.106. PMID 10639511.